gl-v9

GL-V9 is a **synthetic flavonoid derivative** developed as a small molecule modulator with robust anti-inflammatory and antitumor properties. It was designed based on modifications of the structure of wogonin, a naturally occurring flavonoid. Mechanistically, GL-V9 acts as an **AMP-activated protein kinase (AMPK) agonist**, activating the AMPK/FOXO3a pathway, upregulating thioredoxin-1 (Trx-1), suppressing reactive oxygen species (ROS), and reducing oxidative stress and inflammatory response in preclinical models of colitis and tumorigenesis[1][2][3]. Recent studies have demonstrated that GL-V9 suppresses NLRP3 inflammasome activation, enhances autophagic degradation of inflammatory complexes, and inhibits pro-inflammatory cytokine production (IL-1β, IL-6, TNF-α). In cancer models, GL-V9 also synergizes with the chemotherapeutic oxaliplatin, promoting DNA damage in colorectal cancer cells by accelerating the degradation of Wee1 kinase via HSP90 inhibition[3]. Preclinical studies with animal models have focused on ulcerative colitis, colitis-associated colon cancer, and leukemia. GL-V9 is currently at a **preclinical development stage**.

Other names

5-hydroxy-8-methoxy-2-phenyl-7-(4-(pyrrolidin-1-yl)butoxy)4H-chromen-4-one